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Summary
Genetic testing of malignant melanoma in the back of the eye is becoming increasingly warranted due to genetic prognostication and emerging possibilities of personalized treatment regimes. As the majority of posterior uveal melanomas can be treated with eye-conserving radiotherapy, a tissue sample for genetic analysis must be obtained through biopsy. The main goal of this dissertation was to assess transvitreal retinochoroidal (TVRC) biopsy of uveal melanoma in terms of clinical risks and the ability to identify genetic prognostic markers. The ocular complications and especially the potential risk of iatrogenic dissemination of tumour cells following biopsy remain a concern for many ocular oncologists. To evaluate the metastatic risk following TVRC biopsy, we conducted a nationwide retrospective cohort study of patients, diagnosed with intraocular malignant melanoma from 1985 through 2016. During a total of 3.9 and 8.4 thousand person-years of observation for biopsied (35%) and nonbiopsied patients, respectively, we found no statistically significant difference between survival rates of patients who underwent TVRC biopsy immediately before primary treatment and patients where no tumour biopsy was performed.
We evaluated the ocular complications and visual outcome following TVRC vitrector biopsy in a cohort of 85 patients with intraocular tumours diagnosed from 2009 through 2011. There were no signs of tumour seeding during biopsy. Six cases (8%) developed local recurrence adjacent to the primary tumour, which was interpreted as treatment failure rather than seeding from the biopsy. A high incidence of postoperative vitreous haemorrhage entailed an initial decrease in visual acuity (VA). However, the vitreous haemorrhage cleared spontaneously during the first postoperative year in 86.6% of cases and VA improved accordingly. Interestingly, retinal detachment following biopsy was limited and only three patients (3.5%) underwent retinal detachment surgery during follow-up.
Intraocular biopsy carries risk of insufficient sampling. We assessed the yield of the TVRC vitrector biopsy in 123 patients with a posterior intraocular tumour. Sufficient material was obtained for cytological diagnosis in 97.6% of cases and cytogenetic testing of chromosomes 3 and 8 in 97.3% and 96.4% of cases, respectively, when two different genetic analyses were used.
Genetic heterogeneity has previously been proposed in uveal melanoma and carries risk of misclassification. Thus to characterize genetic heterogeneity in uveal melanoma and determine if the genetic profile of TVRC vitrector biopsy reflects the genetic alterations in the tumour, we performed a validation study. Sections from the 24 enucleated eyes were microdissected to evaluate the spatial distribution of genetic heterogeneity. While copy number alterations of chromosome 3 were consistently distributed throughout the tumour in 87%, we found genetic heterogeneity of chromosome 8 in 46% of the tumours. The odds for obtaining a sample with genetic copy number alterations increased towards the base of the tumour (p = 0.049). We compared genetic alterations of chromosomes 3 and 8 obtained by TVRC vitrector biopsy to the 24 matched enucleated tumour eyes. The sensitivity of the TVRC vitrector biopsy to detect genetic aberrations was high; detection of chromosomes 3 alterations was concordant in all cases (100%) while three quarters of chromosome 8 alterations was detected (75%).
We evaluated the prognostic value of the biopsy in a retrospective consecutive cohort study of uveal melanoma patients treated at Rigshospitalet from 2009 to 2012. Both American Joint committee on cancer (AJCC) stage III (HR: 11.0, 95% CI: 1.4-85.6) and aberrations of chromosomes 3 (HR: 6.3, 95% CI: 1.4-28.3) and 8 (HR: 2.8, 95% CI: 1.03-7.8) proved to be independent risk factors for melanoma-specific death in the adjusted Cox model. The 4-year cumulative incidence of melanoma-specific death differed between 0.07% and 50% based on chromosomal status. A normal genetic status of chromosomes 3 and 8 predicted a favourable survival independent of AJCC stage. Still, AJCC staging provided further prognostic stratification among patients with abnormal chromosomes.
In conclusion, the TVRC vitrector biopsy is a safe and reliable method for obtaining a tumour sample for genetic prognostication in uveal melanoma patients. (I) Our data do not support the hypothesis of an increased metastatic risk following TVRC biopsy. (IIa) The ocular complications following TVRC vitrector biopsy are limited and manageable. (IIb) The TVRC vitrector biopsy provides a sufficient yield for genetic testing. The proportion of successful genetic results is increased by the use of two genetic analyses. (III) The TVRC biopsy provided a representative sample for the detection of genetic prognostic markers. The likelihood for detection of copy number alterations might be increased by sampling at the base of the tumour. (IV) Genetic testing of the TVRC vitrector biopsy sample provided accurate stratification of patients with high, intermediate and low risk, based on copy number variations of chromosomes 3 and 8. The prognostic effect of genetic evaluation was further enhanced by evaluation of AJCC staging in patients with chromosome copy number alterations. A normal genetic status predicted a favourable survival independent of AJCC stage.
Summary (Danish)
Genetisk testning af malignt melanom i den bagerste del af øjet giver mulighed for en praecis estimering af prognosen og bliver stadig mere aktuelt i forhold til potentielle muligheder for m alrettet skraeddersyet behandling til den enkelte patient. Da størstedelen af patienterne i dag modtager øjenbevarende str alebehandling, er en biopsi nødvendig for at udtage vaev til genetisk analyse. Det overordnede form al er at undersøge om den trans-vitreale retino-choroidale (TVRC) biopsi har en rolle i behandlingen af patienter med uvealt melanom, herunder en vurdering af de kliniske risici og evnen til at identificere genetiske prognostiske faktorer.
De okulaere komplikationer, isaer den potentielle risiko for spredning af tumor celler i forbindelse med biopsi er fortsat en betydende bekymring og barriere for mange behandlende oftalmologer. Vi evaluerede en national retrospektiv kohorte indeholdende samtlige patienter med uvealt melanom i Danmark fra 1985 til og med 2016. Vi fandt ikke nogen overdødelighed bland biopterede patienter (35%) sammenlignet med ikke-biopterede patienter i løbet af en follow-up periode p a henholdsvis 3,9 og 8,4 tusind person ar.
Vi undersøgte de okulaere komplikationer efter TVRC biopsi i en kohorte af 85 konsekutive patienter diagnosticeret med intraoculaere tumorer fra 2009 til og med 2011. Vi fandt ingen tegn p a lokal tumor udsaed fra biopsien. Seks (8%) patienter udviklede revaekst lokaliseret til den primaere tumor. Vi observerede en høj incidens af postoperativ corpus haemoragi, som medførte en initial forvaerring af visus bland patienterne. Dog observerede vi spontan opklaring af blødningen i 86,6% af patienterne og en tilsvarende forbedring i visus gennem de to første ar. Forekomsten af amotio var lav og kun tre patienter (3,5%) blev opereret for amotio under follow-up perioden.
Intraoculaer biopsi medfører en risiko for utilstraekkelig prøveudtagning. Vi undersøgte udbyttet af en 25G TVRC vitrektor biopsi i 123 konsekutive patienter med en intraoculaer tumor. Tilstraekkeligt materiale blev opn aet til cytologisk diagnose i 97,6% af tilfaeldene og cytogenetisk analyse af kromosom 3 og 8 i henholdsvis 97,3% og 96,4% af tilfaeldene, ved brug af to forskellige genetiske analysemetode.
Genetisk heterogenitet er tidligere blevet p avist i uveale melanomer og medfører risiko for fejl sampling og genetisk fejlklassificering. For at karakterisere genetisk heterogenitet i uveale melanomer samt afgøre, om den genetiske profil af TVRC vitrector biopsien afspejler de genetiske aendringer i tumoren, udførte vi et valideringsstudie. Histologiske snit fra 24 enukleerede øjne blev mikrodissekeret for at evaluere den spatiale fordeling af genetiske forandringer. Mens genetiske forandringer af kromosom 3 var konsistent fordelt gennem hele tumoren i 87%, fandt vi genetisk heterogenitet af kromosom 8 i 46% af tumorerne. Oddsene for at udtage en prøve med genetiske forandringer blev større mod basis af tumoren (p = 0,049). Vi sammenlignede genetiske forandringer af kromosom 3 og 8 opn aet ved TVRC vitrector biopsi med de 24 matchede enucleerede tumor øjne. TVRC vitrector biopsiens sensitivitet til at detektere genetiske afvigelser var høj; P avisning af kromosom 3 aendringer var i alle tilfaelde (100%) konsistente, mens tre fjerdedele af kromosom 8 aendringer blev p avist (75%).
Vi evaluerede biopsiens prognostiske vaerdi i et retrospektivt kohortestudie af uveal melanompatienter behandlet fra 2009 til 2012. B ade TNM (American Joint Committee on Cancer [AJCC]) stadie III (HR: 11,0, 95% CI: 1,4-85,6) og forandringer af kromosom 3 (HR: 6,3, 95% CI: 1,4-28,3) og 8 (HR: 2,8, 95% CI: 1,03-7,8) viste sig at vaere uafhaengige risikofaktorer for melanomspecifik død i den justerede Cox-model. Den 4-arige kumulative forekomst af melanom-specifik død varierede mellem 0,07% og 50% baseret p a kromosom status. En normal genetisk status af kromosom 3 og 8 medførte en god overlevelse uafhaengigt af AJCC stadie. Derimod medførte AJCC stadiet yderligere prognostisk stratifikation blandt patienter med forandringer af kromosom 3 og 8.
Konklusionen er, at TVRC vitrector biopsi er en sikker og p alidelig metode til at udtage en sufficient tumorprøve til diagnostisk bekraeftelse og genetisk prognosticering hos patienter med uvealt melanom (I) Vores data understøtter ikke hypotesen om en øget metastatisk risiko efter TVRC biopsi. (IIa) De okulaere komplikationer, i forbindelse med TVRC vitrector biopsi, er begraensede og h andterbare. (IIb) TVRC vitrector biopsien giver et tilstraekkeligt udbytte til genetisk testning. Endvidere øges andelen af succesfulde genetiske resultater ved brug af to genetiske analyse metoder. (III) TVRCbiopsien leverede en repraesentativ prøve til p avisning af genetiske prognostiske markører i alle tilfaelde. Sandsynligheden for p avisning af genetiske aendringer kan sandsynligvis øges ved prøveudtagning naer basis af tumor. (IV) Genetisk analyse af prøven fra TVRC vitrector biopsien medfører en nøjagtig stratificering af patienter med høj og lav risiko baseret p a genetiske aendringer af kromosom 3 og 8. Den prognostiske effekt af genetisk evaluering blev yderligere forbedret ved samtidig evaluering af AJCC stadie for patienter med aendringer i kromosom 3 og 8. En normal genetisk status af kromosom 3 og 8 i de uveale melanomer medførte en god overlevelse uafhaengigt af AJCC stadie.
Introduction
Malignant melanoma in the uveal layer of the eye is a lethal disease, which causes death due to metastatic spread in half of the patients (Kujala et al. 2003) . Management of the primary tumour has improved dramatically and eye-conserving radiotherapy is successful in local tumour control and preservation of visual function in most cases. Still, survival rates have not improved accordingly and it is hypothesized that metastatic disease arises from micro-metastatic tumour cells already disseminated at the time of the diagnosis (Nichols et al. 2017) . Somatic genetic alterations in uveal melanoma tumours have proven to be highly predictive for metastatic risk and can be used as prognostic markers (Shields et al. 2017b) . Accurate prognostication allows for individualized follow-up and optimized utility of healthcare resources. Estimation of prognosis also facilitates enrolment of high-risk patients into clinical trials of adjuvant systemic treatment at time of diagnosis (Singh et al. 2016) . Multicentre efforts of genetic profiling have identified genes highly specific for uveal melanoma tumorigenesis and led to several potential targeted therapy strategies (Goh & Layton 2016) . Personalized targeted treatment options hold great promise and will hopefully improve the survival of future patients with uveal melanoma. As most patients undergo eye-conserving treatment, a biopsy is needed to obtain tissue for genetic prognostication and profiling. To biopsy, a malignant tumour is still a controversy regarding the theoretical risk of spread. No previous studies have sufficiently assessed this important issue due to challenges caused by the low frequency and late metastasis of uveal melanoma (McCannel 2013) . Furthermore, the small size and precarious location of the uveal melanoma involve risk of insufficient sampling and sight-threatening ocular complications. Uveal melanomas are heterogeneous tumours which poses a risk of misclassification if genetic evaluation is based on a single biopsy sample. Invasive surgical procedures always carry risk and must be weighed against the possible benefits and necessity of the intervention. Prognostic stratification of patients based on genetic profile therefore calls for an evidence-based evaluation of the biopsy procedure in terms of clinical benefits and risks.
Thesis
Accurate estimation of prognosis for patients with uveal melanoma can be acquired through detection of genetic alterations in the tumour and clinical staging. An invasive TVRC biopsy can be performed with minimal risk for the patient's life and eye and provide a sufficient sample for diagnostic and genetic analyses. The genetic profile based on the biopsy sample is representative of the tumour despite potential genetic heterogeneity of uveal melanomas.
Hypotheses
• Does performance of TVRC tumour biopsy cause an increased risk of metastatic disease?
• Does performance of TVRC vitrector biopsy cause severe ocular complications and impairment of visual acuity?
• Does the TVRC vitrector biopsy obtain sufficient tumour material for histopathological and genetic testing?
• Are uveal melanomas genetic heterogeneous?
• Does the evaluation of a single TVRC vitrector biopsy sample cause genetic misclassification due to genetic heterogeneity in uveal melanomas?
• Can genetic profile based on the TVRC biopsy sample provide accurate estimation of the survival of patients with uveal melanoma?
• Can genetic prognostication replace the traditional clinical tumour node metastasis (TNM) staging system?
Background
Uveal melanoma in the eye arises from melanocytes located in the uvea, a pigmented highly vascularized layer in the eye wall. The uvea can be subdivided into an anterior part (iris), an intermediate part (ciliary body) and a posterior part (choroid), the two latter comprising the posterior uveal melanomas which accounts for 96% . Iris melanomas differentiate from the posterior uveal melanomas especially by a favourable 5-year survival rate of 97% (Shields et al. 2008 ). The following thesis will exclusively refer to uveal melanomas located in the choroid and ciliary body.
Epidemiology
Uveal melanoma accounts for the most common primary intraocular malignancy in adults, with an incidence of 6-8 per million person-years in Europe (Virgili et al. 2007 ). The disease often develops in patients between 50 and 70 years of age, with a mean age at diagnosis of 58 years . Uveal melanoma carries an estimated melanoma-specific survival of 70% and 60% at 5 and 10 years, respectively. Ultimately 50% of patients with uveal melanoma die from spread of the disease (Kujala et al. 2003) . Increasing use of eye-conserving radiotherapy has been observed while the use of enucleation as a primary treatment is decreasing (Singh et al. 2011) . However, survival rates have remained poor with no significant improvement during the last 80 years (von Hippel 1936; Singh et al. 2011) . The development of metastatic disease follows a bimodal pattern, with a high frequency of metastases occurring around 3 and 9 years after diagnosis (Demicheli et al. 2014 ). In addition, uveal melanoma is characteristic for late metastases which have been reported to occur up to 34 years after the primary diagnosis (Kujala et al. 2003) . The prognosis after the development of metastatic disease remains poor and the expected median survival ranges from 4-15 months (Augsburger et al. 2009 ).
Clinical management
The symptoms of uveal melanoma are nonspecific and often include decreased vision, floaters or pain . A noninvasive diagnosis of uveal melanoma can be made with a high accuracy based on fundus examination and ancillary testing including ultrasonography, fluorescein angiography, enhanced depth imaging optical coherence tomography and auto-fluorescence (The collaborative Ocular Melanoma Study Group 1998; Shields et al. 2014) . Exudative retinal detachment is detected at time of diagnosis in up to 75% of cases and is strongly correlated with increasing tumour size (Kivel€ a et al. 2001) . Surgical treatment of uveal melanoma includes removal of the eye (enucleation) or removal of the tumour (local resection). Treatment by radiotherapy includes stereotactic radiation, brachytherapy or proton beam radiation. Eye-conserving treatment modalities have largely replaced enucleation which is reserved for eyes with large uveal melanomas or tumours with close proximity to the optic nerve (Damato 2010; Singh et al. 2011) . Observation in small tumours can be justified until growth is documented (Damato 2010) . Uveal melanoma is distinctive for purely hematogenic dissemination due to lack of lymphatic vessels from the eye. Metastases are predominantly found in the liver (90%) and subsequently spread to the lungs and bones (Papastefanou & Cohen 2011) . It has been hypothesized that dissemination of metastatic tumour cells occurs early, even before detection of the primary tumour and remain dormant for years before clinical detectable macroscopic metastases are developed (Eskelin et al. 2000) . There is currently no curative treatment once metastases have formed (Augsburger et al. 2009 ), but early detection and aggressive resection of liver metastases can prolong the metastatic median survival (Mariani et al. 2009 ).
Prognostication
Patient characteristics
Juvenile uveal melanoma occurring in patients younger than 21 years old is rare, but associated with a significantly favourable survival (Petrovic et al. 2014) . Male gender has been proposed to be associated with increased mortality in patients with uveal melanoma (Virgili et al. 2008) . However, no significant prognostic effect of gender was shown for the risk of melanomaspecific death and the finding is likely to be influenced by the presence of competing risks (Kujala et al. 2003) .
Tumour characteristics
It is well established that metastatic risk increases with increasing tumour size in uveal melanoma (Shields et al. 2009 ). Uveal melanomas can be categorized in three defined groups based on tumour height and largest basal diameter (LBD), including small (height <3 mm and basal diameter <10 mm), medium (height = 3-8 mm and basal diameter <15 mm) and large (height >8 mm and basal diameter >15 mm). The corresponding estimated 5-year mortality rates are 16%, 32% and 53%, respectively (Shields et al. 2009 ). The exact causality of increasing tumour size and metastatic disease is not known. It is plausible that large tumours have more time to grow and accumulate genetic alterations which provides the ability to disseminate and form metastases. Large tumour size might also be an indication of accelerated growth rate and thereby represent a more malignant tumour. Lastly, large tumour size might also be associated with increased metastatic risk due to the fact that both the tumour and the metastases have simply been present and growing for a longer time (lead time bias) . Ciliary body involvement and extraocular extension are also factors associated with a poor survival (Kujala et al. 2013) .
A combination of tumour size and anatomical location provided basis for staging of uveal melanoma in the seventh and recently the eight edition of the Cancer Staging Manual of the American Joint Committee on Cancer (Kujala et al. 2013) . Comprehensive international validation has subsequently confirmed the prognostic value of the AJCC staging system (Finger 2009; Shields et al. 2013; Kivel€ a et al. 2016 ).
Histopathological factors
A prognostic classification system based on cytological patterns was proposed by Callender in 1939 (Wilder & Callender 1939) . The categories are based on the shape of the tumour cells and include spindle cells (type A or B) and epithelioid cells. The presence of epithelioid cell type is associated with a worse prognosis. However, a dichotomous differentiation between spindle and epithelioid cells is challenging as most melanomas (86%) contain a mixture of both cells (The collaborative Ocular Melanoma Study Group 1998). The lack of consensus with regard to the number of epithelioid cells needed in tumours to be categorized as either mixed or epithelioid introduces intraand interobserver variability in the classification system (Mudhar et al. 2004 ). Other histopathological factors predicting a bad prognosis include infiltration of macrophages, large nucleoli, high microvascular density and the presence of vascular loops (M€ akitie et al. 1999; Damato et al. 2011 ).
Acquired genetic factors
Uveal melanoma harbours few highly specific gene mutations that activate the G-protein alpha-q signalling cascade, including GNAQ, GNA11, PLCB4 or CYSLTR2 in a mutually exclusive pattern (Van Raamsdonk et al. 2010; Johansson et al. 2016; Moore et al. 2016) . These genes seem to be necessary for initiation but not sufficient for uveal melanoma proliferation and do not seem to influence prognosis (Robertson et al. 2017 ). In addition, uveal melanomas often harbour somatic alterations of BAP1, SF3B1 or EIF1AX in a partially exclusive pattern. These mutations are thought to advance melanoma progression and are essential for the metastatic potential of the disease.
Accelerating development of genetic prognostication in uveal melanoma was initiated by the landmark reporting of association between loss of chromosome 3 and inferior prognostic outcome in 1996 (Prescher et al. 1996) . Genetic prognostication can be performed by the evaluation of loss or gain of chromosomes 1p, 3, 6 and 8 (copy number variations), somatic gene mutations of BAP1, SF3B1 and EIF1AX or by assessing expression (mRNA) levels of multiple genes (Gill & Char 2012; Yavuzyigitoglu et al. 2017) . Increasing evidence demonstrates functional associations between the genetic alterations and has allowed for a classification of four distinct molecular subtypes with different risk of metastatic disease ( Fig. 1) Robertson et al. 2017; Yavuzyigitoglu et al. 2017) .
High risk of metastatic formation is greatly correlated to loss of chromosome 3 (monosomy 3) and gain of chromosome 8q (Shields et al. 2011; Ewens et al. 2013) . The amount of additional chromosome 8q copies is even proportional with increasing risk of metastatic disease (Versluis et al. 2015) . Copy number variations of chromosomes 3 and 8 are often accompanied by additional alterations including loss of chromosomes 1p, 8p, 6q and 16q (Trolet et al. 2009; Yavuzyigitoglu et al. 2017) . The combination of monosomy 3, disomy 6, gain of 8q and loss of 8p entailed the worst prognosis (HR = 31.6) in a study evaluating cytogenetic changes among 534 cases (Shields et al. 2017b) . BRACA associated protein 1 (BAP1) is a tumour suppressor gene located on chromosome 3 affecting histone modification. Tumours with monosomy 3 often harbour a somatic mutation in the BAP1 gene located on the remaining copy of chromosome 3 (Fig. 1) . This is in accordance with Knutsson two hit model where, in this case, BAP1 function is inactivated by accumulating genetic alterations affecting both copies of the gene (Knudson 1971) . BRACA associated protein 1 (BAP1) alterations can also manifest as a germline mutation resulting in accumulation of uveal melanoma among other cancers in affected family members (Wadt et al. 2012) .
Simultaneous assessment of mRNA expression including multiple genes has identified two distinct subgroups which are referred to as class 1 and class 2, where class 2 is highly predictive of metastatic disease (Onken et al. 2012) . Still, discordance between monosomy 3 and gene expression profile (GEP) 2 is shown in 20.8% of cases (Onken et al. 2012) .
Intermediate risk profile includes normal copy number of chromosome 3, but gain of chromosome 8q, which is often accompanied by loss of chromosomes 1p and 6q (Robertson et al. 2017) . Recurrent somatic mutations in SF3B1 have been identified, while BAP1 mutations are seldom seen in the absence of chromosome 3 loss. Somatic mutations in SF3B1 are associated with late metastases (Yavuzyigitoglu et al. 2016a) . Initially, GEP class 1 predicted a favourable survival (Onken et al. 2004 ). However, prolonged follow-up identified a subgroup of patients among class 1 cases which went on to develop metastatic disease. Class 1 was therefore divided into class 1a and class 1b, where 1b predicts an intermediate risk of metastatic disease (Plasseraud et al. 2017) . Increased expression of the gene PRAME, identified by a high level of PRAME mRNA, is predictive of metastatic disease among class 1 patients. Assessment of PRAME expression can therefore be used to differentiate between intermediate (1b) and low-risk (1a) patients ).
Low risk is associated with a normal copy number of especially chromosomes 3 and 8. Gain of chromosome 6p is also associated with a favourable survival (Damato et al. 2009 ). The lowrisk profile is frequently accompanied by somatic mutations in EIF1AX (Yavuzyigitoglu et al. 2017 ) and GEP class 1a .
Stratification of patients based on chromosome 3 status resulted in a 10-year mortality rate of 100% among patients with chromosome 3p loss compared to a 30% mortality rate among patients who did not harbour that genetic change (Kilic et al. 2006 ). In addition, 5-year mortality estimates ranging from 4% to 39% based on cytogenetic profile of chromosomes 3, 6 and 8 have been reported (Shields et al. 2017b) . In comparison, stratification of patients according to AJCC tumour size provided 5-year mortality estimates ranging from 8% (T1) to 30% (T4).
It has been proposed that GEP outweighs all other prognostic factors and can be used independently ). In contrast, Damato et al. (2011) have developed an extensive online prognosticator tool (LUMPO) which integrates cytogenetic, clinical and histopathological prognostic factors and uses advanced algorithms to provide an individual relative risk.
Genetic analysis techniques
The most widely used cytogenetic techniques for detection of genetic alterations in uveal melanoma include karyotyping, fluorescence in situ hybridization (FISH), array comparative genomic hybridization (CGH), single nucleotide polymorphism (SNP) array, microsatellite analysis (MSA), multiplex ligation-dependent probe amplification (MLPA) and gene expression profiling (GEP) (Werdich et al. 2013) .
The presence of nonrandom chromosomes 3 and 8q alterations in uveal melanoma was initially discovered by karyotyping in 1990 (Prescher et al. 1990 ). The technique allows for evaluation of numeric and structural changes of all 23 chromosome pairs. The analysis is performed on mitotic cells and therefore requires fresh tissue. The use in clinical practice is limited by the cost, heavy laboratory work load and the need for an experienced cytogeneticist. In addition, the low resolution only allows for detection of gross chromosomal changes (Dogrus€ oz & Jager 2017) .
Numerical evaluation of chromosome copy number can also be performed by FISH. Fluorescent-labelled DNA probes are bound to their matching complementary chromosomal region. The FISH probe can either target the entire chromosome, the centromere or a specific locus (Aronow et al. 2012) . The technique allows for direct visualization of the targeted chromosome region through fluorescent microscopy as shown in Fig. 2 .
Multicolor FISH (M-FISH) is not routinely performed, but can be applied in selected cases after karyotyping to provide additional information on structural changes and copy number variations of all chromosomes (Fig. 3) . The technique requires the presence of tumour cells in metaphase.
Array Comparative Genomic Hybridization (aCGH) provides an estimation of genomewide copy number variations relative to a reference sample (Trolet et al. 2009 ). Individual labelling of DNA from the two samples and hybridization of cloned DNA is performed. Visualization of relative gain and loss of all chromosomes can be identified by the use of a fluorescent microscope and specialized software. Copy number estimation of chromosomes 1p, 3, 6 and 8 can be assessed by MLPA with a high sensitivity (Damato et al. 2009 ).
The test provides quantification of the targeted chromosomes in relation to reference chromosomes which are not usually altered in uveal melanoma as shown in Fig. 4 .
The shared limitation of the abovementioned techniques is that they lack ability to differentiate between the two chromosome copies. Thus, loss of one copy of chromosome 3 followed by duplication of the remaining copy (uniparental isodisomy [UPID] 3) would not be detected. Thus, a case of bi allelic loss of BAP1 function, which undergoes UPID 3, could be misclassified as disomy 3. The occurrence of isodisomy 3, with loss of BAP1 function, has been reported to occur in 2 of 25 disomy 3 cases (8%) (van de Nes et al. 2016) .
In contrast, copy number analyses based on detection of single nucleotide polymorphisms (SNP array) or micro satellites (MSA) can differentiate between the allele inherited from the mother and father, respectively (Dogrus€ oz & Jager 2017) .
Increasing use of DNA mutation analysis performed by Sanger sequencing or Next Generation Sequencing has been applied to uveal melanoma research and management as well. New targeted essays are developed so that next-generation sequencing can allow for a simultaneous assessment of selected gene mutations and chromosomal copy number (Smit et al. 2018) .
In contrast to the above-mentioned DNA-based methods, gene expression profiling (GEP) uses the expression level of multiple genes to identify the profile of the tumour (Plasseraud et al. 2017) . While all DNA-based methods are limited by their risk of sampling error due to intratumoral heterogeneity, it is proposed that gene expression profiling is less affected by genetic heterogeneity (Onken et al. 2010 ).
Tumour biopsy in the posterior segment
The use of tumour biopsy in the management of uveal melanoma has been controversial as clinical assessment enables a high accuracy of diagnosis (99.7%) in medium and large sized melanomas (The collaborative Ocular Melanoma Study Group 1998). Furthermore, eye-conserving radiotherapy offers excellent tumour control along with a chance to retain visual function of the eye. The possible risk of inadequate sampling, iatrogenic ocular morbidity and the risk of extraocular tumour seeding have traditionally reserved the use of intraocular tumour biopsy for special cases with a significant diagnostic uncertainty (Eide & Walaas 2009 ). During the last two decades, the indication for intraocular biopsy has been reinforced due to the evolving possibilities of genetic prognostication.
Approach
In the Trans-scleral (direct) approach, the sclera is punctured over the tumour and the tumour sample is obtained from the outside directly through the sclera leaving the retina intact. The procedure is most feasible when the tumours are located anteriorly to or in relation to the equator. The transvitreal (indirect) approach entails anterior entry through pars plana opposite of the tumour location and advancement through the vitreous body and retina into the choroidal tumour. The different techniques for obtaining a sample in the posterior segment are summarized in Table 1 .
Excisional biopsy
Trans-scleral excisional biopsy includes lamellar incision and removal of a scleral flap to obtain a tissue sample directly from the exposed tumour. The procedure provides a large sample feasible for histopathological assessment. However, it is only performed at a few centres as it requires special surgical skills and has previously been shown to 46,XX, dic(3;6),+6,der(6)dic(6;6)ins(13),der (7)t(7;16),dic(6;7)ins(3),der(6;13),der(8;13),del (16),der (19) carry a significant risk of orbital tumour dissemination (Jensen & Andersen 1959 ).
Incisional biopsy
Transvitreal incisional biopsy also obtains large samples adequate for histopathological assessment. The procedure includes a full 23G/20G 3 port pars plana vitrectomy followed by retinal diathermy to minimize bleeding (Seregard et al. 2013) . A 20G diamond knife is used to cut a 1 9 1 mm retinal incision followed by the excision of a 1 mm 3 tissue sample. The tumour sample is grasped and removed through the sclerotomies by an end-gripping forceps. The procedure entails a significant risk of retinal detachment (33%) and is predominantly applied in a few centres, when other less invasive biopsy methods have failed to produce a sufficient sample (Seregard et al. 2013 ).
Essen forceps biopsy
Transvitreal biopsy using an Essen forceps (Akgul et al. 2011 ) requires a 23G 3 port pars plana vitrectomy followed by a 0.6 mm incision in the retina to allow advancement of the open Essen forceps into the tumour (Akgul et al. 2011 ). The sample is grasped by the forceps and withdrawn through the vitreous cavity and scleral port. The procedure entails a potential risk tumour seeding in samples larger than 0.6 mm, as they can get stuck at the entry site of the scleral port (Akgul et al. 2011 ).
Fine-needle aspirations biopsy
Fine-Needle aspiration biopsy (FNAB) is widely used and can be performed both transvitreally and trans-sclerally. The procedure requires an assistant to aspirate the sample while the surgeon advances the needle inside the tumour (McCannel 2013) . It is cheap and has been shown to carry little risk for ocular complications (McCannel et al. 2012) . The main limitation is low yield and consequential risk of insufficient sampling (Sen et al. 2006) . While the trans-scleral approach requires the tumour to be at least 3 mm in height, the transvitreal approach allows for direct transpupillary visualization during the procedure and sampling of small tumours (Eide & Walaas 2009 ). The procedure can be combined with prior removal of the vitreous body (vitrectomy) to reduce the risk of persistent vitreous haemorrhage (Reddy et al. 2017 ).
Vitrectomy-assisted transvitreal biopsy
Transvitreal retinochoroidal (TVRC) biopsy performed with a 25G or 27G vitreous cutter (Fig. 5) , yields adequate specimens for cytogenetic and cytopathologic examination (Bechrakis et al. 2002) . The procedure involves a three-port pars plana setup. The vitreous cutter is advanced without cutting (Sen et al. 2006; Abi-Ayad et al. 2013; Grewal et al. 2017 ).
Seeding of the tumour during intraocular biopsy in uveal melanoma remains a significant concern, but has been limited by refined techniques and smaller cannulas (Fig. 5) (Bechrakis et al. 2002) . Still, to reduce potential risk of tumour seeding some centres advise that biopsy is performed after completion of tumour radiation as genetic prognostication seems to be unaffected shortly after irradiation (Hussain et al. 2016 ). However, others have shown that radiation can alter genetic testing in uveal melanomas and that the radiation effect might depend on the time interval between radiation and genetic testing (Dogrus€ oz et al. 2015) .
Material and Methods
Material
The nationwide Eye Pathology Institute, Copenhagen University, has systematically collected and stored records of all enucleated eyes, biopsy and autopsy eye-specimens in Denmark from 1943 through 2015. We manually reviewed these archives to identify all histopathologically verified cases of uveal melanoma. Patients treated with eye-conserving brachytherapy that were not biopsied or autopsied could not be found in the records of the Eye Pathology Institute. Eye-conserving brachytherapy is a highly specialized treatment which has only been performed at the two national referral centres in Denmark, Rigshospitalet Copenhagen University hospital and Aarhus University hospital. We were therefore able to identify uveal melanoma patients with no histopathological confirmation through a search in the local clinical records of these two highly specialized University hospitals. The national Ocular Oncology Group database was established in 2014 and contains clinical data from patients with uveal melanoma treated since 1997 and is prospectively maintained. We used this database to supplement our cohort with clinical data. Dr. Erick Scherfig introduced TVRC biopsy at the department of Ophthalmology Rigshospitalet and kept meticulously updated records including clinical data on all patients with uveal melanoma that underwent biopsy from 1984 to 1994 (Jensen et al. 1997) . We used these records to supplement our cohort. All data was merged in the Copenhagen Epidemiological Uveal melanoma Study database (COEUS) (Microsoft Access 2010; Microsoft, Inc., Redmond, WA, USA). We created the COEUS database to contain detailed clinical and histopathological information on all included choroidal and uveal melanoma patients.
Registry data
Identification of eligible patients with uveal melanoma was primarily based on histopathological and clinical records as described and then supplemented by data linkage to other national databases (Fig. 6) .
The Danish Civil Registration System (CRS) ensures non ambiguous individual data linkage through a 10 digit personal identification number (CPR number), which has been issued upon birth or immigration to all Danish residents since 1968 (Pedersen 2011) . The CRS contains continuously updated data on vital status and emigration among other demographic variables.
The Danish Cancer Registry (DCR) was established in 1943 and contains prospectively updated data on all cancer incidences in Denmark (Gjerstorff 2011). To cross-check data in our cohort, we performed a search in the Danish cancer registry for uveal melanomas from 1943 to 2014. Due to delays in the DCR, updated data from 2015 and 2016 was not available at the time of study. Distinction between uveal melanomas located to the iris and ciliary body is challenging, as the same coding applies for both (C69.4). In addition, some uveal melanomas were coded as unspecified malignancies in the eye and could therefore not be distinguished from other ocular malignancies such as lymphoma and conjunctival melanoma. Due to these limitations of eye cancer registry data, we chose to only include additional cases identified through the DCR if their diagnosis could be validated through retrieval of clinical charts or histopathological descriptions.
The Danish Pathology Registry (DPR) contains information on all histopathological diagnoses in Denmark (Bjerregaard & Larsen 2011) . Computer registration of pathology data in Denmark was initiated in 1970 and since 1990 all pathology departments throughout Denmark have been obliged to perform electronic registration of all pathological specimens examined.
The Danish Registry of Causes of Death (DRCD) was established in 1875 and computerized in 1970 (HelwegLarsen 2011). The DRCD is essential in much research as it offers the opportunity to evaluate cause-specific mortality in epidemiological studies. The cause of death is retrieved from death certificates, which are issued by a physician according to guidelines from World Health Organization (WHO). The underlying cause of death is defined as the disease or injury which initiated the chain of diseases which ultimately led to death. The validity of the data might be affected by the decreasing autopsy rate and relies mainly on the correctness of the individual physicians' interpretation of the death-causing events (Helweg-Larsen 2011). 
Study design and study populations
Metastatic risk following biopsy (I)
Uveal melanoma poses several challenges including low frequency and late metastases, which we have over-come to our best ability by performing a nationwide cohort study including all cases from Denmark and using registry data for long-term follow-up (Fig. 6) . We collected data from 1741 patients with choroidal or ciliary body melanoma treated in Denmark from January 1985 through December 2016 (Fig. 7) . We excluded patients where AJCC stage could not be obtained due to lack of information on tumour characteristics (n = 44). We also excluded patients that underwent more extensive invasive surgery (n = 33) as we hypothesized that these procedures might pose a different dissemination risk and might compromise the interpretation of the study results. We also excluded patients were no treatment was performed as this presented a highly heterogeneous group of either very small melanomas that only underwent observation or advanced melanomas that had already metastasized at time of diagnosis.
Included patients all underwent brachytherapy or enucleation as the primary treatment and were stratified according to whether or not they had a transvitreal biopsy performed. The incidence of biopsied patients varied in different time period as shown below (Fig. 8) .
Ocular morbidity and tissue yield (II)
We conducted a retrospective consecutive case series to evaluate the ocular complications and tissue yield of the vitrectomy-assisted biopsy. We evaluated a total of 153 patients presenting with a suspected posterior intraocular tumour at the department of Ophthalmology Rigshospitalet from January 2009 through December 2011. We excluded patients where a biopsy was not performed. Histopathological evaluation was performed in all patients and genetic evaluation was performed in cases of uveal melanoma (Fig. 9) . Ocular complications could be evaluated in the 84 patients who underwent eye-conserving therapy and in one patient who underwent deferred enucleation 18 days after biopsy.
Genetic heterogeneity and validity of the biopsy (III):
We performed a validity study to evaluate genetic heterogeneity and sensitivity of the biopsy. All uveal melanomas treated at Rigshospitalet from January 2009 through December 2013 were evaluated for eligibility of the study (Fig. 10) . To validate the genetic result from the TVRC vitrector biopsy, we included patients who were biopsied and enucleated during the same surgical procedure. We compared genetic profiles from matched samples of the TVRC vitrector biopsy and the enucleated eye. To evaluate the heterogeneity we chose tumours of at least 5 mm in height where microdissection of at least three tumour samples was possible given the technical limitations.
Prognostic value of genetic profile and AJCC staging (IV) To evaluate the effect of prognostic biopsy and AJCC staging, we performed a retrospective cohort study. A total of 153 patients with choroidal or ciliary body melanoma treated at Rigshospitalet from January 2009 through December 2012 were evaluated for this study. Patients with genetic results on chromosomes 3 and 8 obtained through biopsy were included in the final study population (Fig. 11) .
Clinical data
Staging was performed for the entire cohort in accordance with the AJCC staging system (AJCC staging manual 8th edition, Springer, NY, 2017. Tumour size, ciliary body involvement and extra scleral extension were based on histopathological information from the pathology rapport in enucleated eyes. In cases of eye-conserving treatment, tumour size was determined by ultrasonography and anatomical location was based on clinical observations described in the clinical chart. We recorded retrospective detailed clinical data for the subset of patients treated at Rigshospitalet from 2009-2011. Information regarding VA (Snellen), presence of vitreous haemorrhage, retinal detachment and other possible complications were obtained from the clinical charts for each visit. In patients where second surgery was performed, the indication and procedure were noted.
Transvitreal retinochoroidal biopsy
All biopsies performed after 1984 have been obtained by a three-port pars plana approach through the vitreous body and retina into the choroidal tumour prior to 2009, the biopsy procedure included a full vitrectomy and laser application around the retinotomy site. The minimally invasive vitrectomy-assisted biopsy, performed since 2009, avoided full vitrectomy and left the retinotomy untreated (Fig. 12) . Tumour tissue was obtained by a vitreous cutter (25G) (Bagger et al. 2013) , fine-needle aspiration biopsy (20G or 25G) (Scherfig et al. 1989) or by an Essen Biopsy forceps. All patients with validated histopathological diagnosis of uveal melanoma were enucleated or underwent brachytherapy.
Methods
Genetic data
Reports describing copy number variations of chromosomes 1p, 3, 6 and 8 were available in the clinical charts for patients treated at Rigshospitalet since 2009. (Fig. 13) . The probes are visualized and counted through fluorescence microscopy. At least 100 cells are evaluated by two technicians and copy number variations in more than 10% of the cells were used as a cut off in the present studies.
Multiplex
Ligation-dependent Probe Amplification (fresh tissue)
Multiplex ligation-dependent probe amplification analysis of the TVRC biopsy was available in most cases and has been performed consecutively on all patients with uveal melanoma diagnosed since 2012. DNA is extracted using the QIAamp DNA Micro Kit (Qiagen, Hilden, Germany), followed by standard sodium acetate/ethanol precipitation for optimal purity. Evaluation of loss or gain of the chromosomes 1, 3, 6 and 8 is performed using the SALSA MLPA KIT P027-B1 Uveal Melanoma (MRC-the Netherlands), where probes are ligated to specific DNA sequences on the four chromosomes (Fig. 13 ). In addition, 12 reference probes are ligated to chromosomes rarely affected by abnormalities in uveal melanoma. The signal intensities of the various probes are measured using capillary electrophoresis on a Genetic Analyzer 3130xl (Applied Biosystems Foster City, CA, USA). The signal intensity of each probe is normalized to the signal intensity of each reference probe and the relative amount of each target sequence is calculated using the Coffalyzer.Net data analysis software from MRCthe Netherlands.
MLPA (formalin-fixed paraffin embedded)
To evaluate genetic heterogeneity in study III, formalin-fixed paraffin embedded (FFPE) eyes were collected and 4 9 8 lm consecutive sections were cut from the tissue blocks. The uveal melanomas were microdissected in accordance to a hexagonal grid of 3.5 mm as shown in Fig. 14. The size of the hexagons was based on an initial pilot study and chosen as the smallest possible sample which would still produce sufficient DNA for MLPA analysis. The location of the microdissected sample was registered with a co-ordinate set, the first indicating location from base to apex and the second describing location from the optic nerve to the anterior chamber. The samples were transferred into individual Eppendorf tubes which were labelled according to location. The specimens were deparaffinized and DNA was extracted using a purification kit according to the manufacturer's instructions (Maxwell 16 FFPE Plus LEV DNA; Promega, Madison, WI, USA). Multiplex ligation-dependent probe amplification (MLPA) analyses were performed as described above. The results from each sample were summarized as shown in Fig. 14.
Outcome and follow-up
At Copenhagen University Hospital, all patients treated with brachytherapy are followed up every 6 months by an eye examination until 5 years after treatment. Between 5 and 10 years after brachytherapy the patients are examined yearly. In addition, patients are offered a 15-, 17-and 20-year visit. Patients with abnormal copy number of chromosomes 3 and/or 8 are offered an extended follow-up including abdominal ultrasonography and chest X-ray prior to each visit. A liver biopsy is performed if imaging is suspicious for a metastatic lesion to confirm spread of the disease.
Evaluation of melanoma-specific mortality: In cohort study I and IV, outcome was all-cause and melanomaspecific mortality (death due to uveal melanoma metastases). For all causes, exact date of death could be retrieved from the Civil Registration System. Evaluation of melanoma-specific death was performed in a stepwise manor depending on available information in each case. The level of certainty was established in accordance to guidelines from the COMS group (Moy et al. 2001) . We retrieved information from the Danish National Pathology registry and reviewed descriptions concerning malignant disease in all cases.
(1) If the patient were autopsied, the conclusion from the examination was used to determine cause of death.
(2) Uveal melanoma-specific death was registered if the patient had histopathologically confirmed malignant melanoma metastases with no description of primary cutaneous melanoma. (3) Uveal melanoma-specific death was registered if the clinical chart was available and contained description of metastatic lesions on clinical imaging or if the notes describing the patient's final illness involved metastatic melanoma. (4) Linkage to the Danish Registry of Causes of Death and the Danish cancer registry was used to improve the evaluation of melanoma-specific death in cases where clinical and histopathological follow-up data were not available (study I). The registry revealed a historical misclassification where the underlying death cause for the majority of patients with metastatic uveal melanoma was coded as metastatic cutaneous melanoma. As the coding is sometimes performed by physicians with limited insight into the patients' medical history we developed the criteria's shown below to identify cases in our cohort that died from uveal melanoma metastases (Table 2 ).
Previous registry-based studies evaluating survival of patients with uveal melanoma have encountered similar challenges and have used relative survival as an approximation of melanoma-specific death (Bergman et al. 2003; Isager et al. 2006 ). The relative survival presents the excess survival and is a ratio between the observed and expected survival in a similar population group (Isager et al. 2006 ). Relative survival represents a statistical estimate rather than a confirmed biological event. We wanted to approach the true metastatic incidence and therefore made efforts to reach the best possible level of accuracy on melanoma-specific death by evaluating all available information including clinical, pathological and registry data in each case as described above.
Statistical methods
Survival analyses
In survival analyses patients are observed from a given time-point, in this case the day of primary surgery/ treatment, and are then 'under risk' until the event of interest occurs, that is, death or until they are censored due to end of follow-up. The main advantage of survival analyses is that they account for censored data as all study subjects are not followed up for the same amount of time.
Kaplan-Meier
In study II, spontaneous recovery of vitreous haemorrhage and retinal detachment were evaluated with Kaplan-Meier estimates to account for different length of follow-up. Patients were censored if the following events occurred before recovery: End of follow-up, death, enucleation, vitrectomy, or retinal detachment surgery. The Kaplan-Meier model is simple and easy to interpret, however is does not account for competing events and can therefore cause incorrect estimates Table 2 . Criterias for identification of melanoma-specific death.
Step
The (Kim 2007 ).
Cumulated incidence with competing risk
We chose to present absolute risk by the cumulative incidence function in study I and IV. This presentation accounts for competing risks but without adjustment for covariates. We believe that this is an appropriate univariate presentation when evaluating melanoma-specific risk. Uveal melanoma occurs in patients aged 50-70 years old, therefore death due to other causes possess a significant competing risk which could lead to biased results if not accounted for.
Cox regression
We used multivariate Cox regression in study I and IV to estimate the rate (hazard ratios) of melanoma-specific and allcause death while accounting for potential confounders. In study IV we evaluated the melanoma-specific mortality rate associated with increasing AJCC stage (I-III) and CNVs of chromosomes 3 and 8. In study I we evaluated the hazard ratio for performance of biopsy while adjusting for potential confounders including age, gender, AJCC stage, primary treatment, place of treatment and calendar year. We believe that this approach is appropriate to analyse our research questions. Although models for relative risks that differentiate according to cause are available, such as the Fine and Grey model, we do not believe that it should be used as the only model approach, as the effect estimates from risk regression models cannot be interpreted directly as relative risks (Andersen et al. 2012 ).
Competing risk regression
We used the Fine and Grey model as a sensitivity analysis in addition to the Cox regression estimates in study I to prevent bias from competing risks.
The chi-square test for trend
We used the chi-square test for trend to evaluate if the amount of tumours with an abnormal genetic profile increased with increasing tumour stage. Copy number variations of chromosomes 3 and 8 were entered as dichotomous categorical data being either normal or abnormal. American Joint committee on cancer (AJCC) tumour size (1-4) and AJCC tumour stage (I-IV) was entered as ordered categorical data.
Sensitivity and specificity
The sensitivity of a diagnostic test is defined as the percentage of individuals with a disease who test positive. In study III, sensitivity was defined as the percentage of uveal melanoma tumours with genetic aberrations of chromosomes 3 or 8 which also showed genetic aberrations in the matched TVRC biopsy. Specificity is defined as the percentage without the disease that test negative. The evaluation of false positives did not make sense to perform in this setting as we did not have a gold standard test which could conclusively exclude that genetic aberrations detected by the biopsy and missed in the enucleated tumour sample were not real. Thus an evaluation of specificity was not performed in study III.
The Wilcoxon signed rank test
To evaluate if genetic tumour heterogeneity was associated with increasing tumour size we used the Wilcoxon signed rank test as our data did not follow a normal distribution. We compared tumour size in the genetic homogenous and heterogeneous tumours. The following values were used to describe tumour size: LBD, tumour height, AJCC tumour size (1-4) and total number of microdissected hexagons. Genetic heterogeneity of chromosomes 3 and 8 was entered as either present or not present.
Mixed effects logistic regression
The association between a binary outcome and co-variables can be assessed by logistic regression in terms of odds ratio. Study III compared the association of the binary outcome of normal or abnormal status of chromosomes 3 and 8 and the numerically geographic location of the sample (base to apex and posterior to anterior). The mixed model design was used to incorporate the fact that micro dissected samples were not independent but belonged to a group of samples originating from the same tumour.
Statistical software SPSS statistics version 20.0 (IBM Corp, Armonk, NY, USA) and SIGMAPLOT software version 11.0 (Systat Software, Inc., San Jose, CA, USA) were used in study II. Descriptive SAS, version 9.3 and ENTERPRISE GUIDE version 5.0 (SAS Institute, Cary, North Carolina, USA) was used for study III. The statistical analyses in study I and IV were performed in R including R studio IBM and in collaboration with statistician Klaus Kaae Andersen, the Danish Cancer Society.
Ethical considerations
The study was conducted in accordance with the tenets of the Declaration of Helsinki. All studies were performed retrospectively and did not involve any harm or contact to the patients. 
Main Results
Is transvitreal biopsy dangerous to the patient? (I)
A total of 1637 patients with uveal melanoma were followed for a total of 3.9 and 8.4 thousand person-years of observation for biopsied and nonbiopsied patients, respectively. Patients that underwent biopsy (35%) presented with smaller tumours (p < 0.001) and younger age (p < 0.001) at time of diagnosis. We found no significant increase in all-cause mortality (HR: 1.07, 95% CI 0.89-1.26, p = 0.47) and melanoma-specific mortality (HR: 1.11, 95% CI: 0.89-1.39, p = 0.35) among biopsied patients compared to nonbiopsied patients. In addition, cumulative incidence of melanomaspecific death, with death due to other causes as a competing risk, showed no increased mortality risk in biopsied patients (Fig. 15) .
Is performance of TVRC biopsy dangerous to the eye? (II)
Local tumour seeding
In six patient (8%) a local recurrence was observed and treated with ruthenium brachytherapy (n = 1) or enucleation (n = 5). There was no tumour growth located at the biopsy entry site. All recurrent tumour lesions were located in relation to the primary tumour.
Vitreous haemorrhage
Eighty-two patients (96.5%) presented with vitreous haemorrhage on the first day after surgery. In 71 of the patients (86.6%) the vitreous haemorrhage cleared spontaneously within 2 years. Five patients (5.9%) underwent vitrectomy due to persistent vitreous haemorrhage. Six patients with vitreous haemorrhage were withdrawn from the analysis, due to either retinal detachment surgery (n = 1 ptt.), enucleation (n = 1 ptt.), or death (n = 4 ptt.).
Retinal detachment
At the time of diagnosis a total of 55 (64.7%) patients presented with a retinal detachment secondary to the tumour. The secondary retinal detachment was unaffected by the transvitreal vitrectomy-assisted biopsy and reattached spontaneously within 2 years in all but one case. Following biopsy, an additional five patients (16.7%) developed retinal detachment. Three patients (3.5%) underwent retinal detachment surgery during follow-up.
Visual acuity
All patients who presented with a VA below 6/12 (<0.5) prior to treatment, had a bad visual outcome equal to or below 6/60 (≤0.1). The proportion of patients that maintained a good VA of at least 6/12 (0.5) during follow-up is shown in Fig. 16 . At the time of diagnosis 48 patients (56.5%, total n = 85ptt.) presented with a VA of at least 0.5. A VA of at least 6/12 (0.5) was preserved in 27 (36.0%, total n = 75ptt.), 15 (36.6%, total n = 41 ptt.) and 7 (43.8%, total n = 16) patients during 1, 2 and 3 years of follow-up, respectively. In Fig. 16 we have added our VA data from all patients with uveal melanoma, who underwent biopsy at Rigshospitalet from 2009 through 2016.
Is the yield of the TVRC biopsy sufficient for genetic testing? (II)
The obtained sample was sufficient for histopathological assessment and diagnosis in 121 patients (97.6%). Examples of Hematoxylin & Eosin (H&E) stained samples obtained by TVRC vitrector biopsy (histopathology and cytospin) is shown in Fig. 17 .
Forty-four patients with uveal melanoma underwent enucleation during the study period. Accordance was observed in all cases in regard to diagnosis of the biopsy sample and the enucleated eye. There was agreement of melanoma cell type, between the biopsy sample and the enucleated eye in 26 cases (59.1%). The frequency of successful genetic testing of chromosomes 1p, 3, 6 and 8 is summarized in Table 3 . Fig. 15 . 2=biopsied patients, 3=non-biopsied patients. Cumulative incidence of melanomaspecific death in biopsied patients was not increased compared to non-biopsied patients. *Death due to other causes is shown as a competing risk and was significantly higher (p = 0.002) among non-biopsied patients. (Bergman et al. 2005) .
Is there genetic heterogeneity in uveal melanomas? (III)
A total of 177 micro dissected areas from 24 FFPE eyes yielded usable MLPA results. The MLPA results showed heterogeneity for chromosome 3 alterations in three tumours (13%) and heterogeneity of chromosome 8 alterations in 11 tumours (46%). The odds of detecting chromosome alterations in a microdissected sample increased towards the base of the tumour (odds ratio: 1.65, p = 0.049). There was no difference in tumour size between the 13 heterogeneous tumours and the 11 homogenous tumours (AJCC tumour size [1] [2] [3] [4] ; p = 0.82, tumour height; p = 0.38 and LBD; p = 1). Multiplex ligation-dependent probe amplification (MLPA) results were summarized and remapped to their original location in the tumour in each case (Fig. 18) .
Can we trust the genetic results from a transvitreal vitrectomy-assisted biopsy? (III) MLPA had a higher sensitivity than FISH (100% versus 90%). However, multiple copies (polysomy) of one or more chromosomes were only detected with FISH in three patients (Fig. 19 ). There was a higher sensitivity for detection of chromosome 3 alterations than chromosome 8 alterations, as shown in Table 4 .
Is it possible to estimate risk of metastatic disease from genetic evaluation of the transvitreal vitrector biopsy? (IV) There was a significantly increased risk of melanoma-specific mortality associated with abnormalities in chromosome 3 and 8 (HR: 6.3, 95% CI: 1.4-28.3 and HR: 2.8, 95% CI: 1.03-7.8, respectively.) Regardless of AJCC stage, normal genetic status of chromosomes 3 and 8 predicted a favourable survival (Fig. 20) . In patients with abnormal copy number of chromosomes 3 and/ or 8, AJCC staging provided further stratification of patients (Fig. 20) . There was a trend towards association between larger AJCC tumour size and likelihood of genetic alterations (p = 0.069).
To validate our findings, we conducted a collaborative project with the Leiden group in 2016, merging our cohort of 247 Danish patients with 275 patients treated for uveal melanoma in Leiden ). In addition, we created a nomogram based on the effect estimates from the Cox regression so that predictions for survival at different time-points could be evaluated manually as described by Harrell (Harrell 2001) (Fig. 21) . Only the significant parameters of melanoma-specific death from the collaborative study were included in the nomogram. Increasing AJCC stage, monosomy 3 and gain of chromosome 8q contribute individually to decreased probability of survival.
Discussion
The performance of TVRC vitrector biopsy in patients with uveal melanoma permits sufficient and representative sampling of tumour tissue for genetic testing. Thus, the TVRC biopsy facilitates accurate identification of high-risk patients and individualized follow-up. The frequency of intraocular complications following the procedure was limited and no increased risk of metastatic disease was detected.
Risk of tumour cell dissemination
Mechanical disruption of intratumoral blood vessels during the biopsy procedure carries a potential risk of systemic tumour cell dissemination which might cause increased metastatic formation (Glasgow et al. 1988 ). This hypothesis was not supported by our study, as we found no apparent difference in melanoma-specific and all-cause mortality rates among patients with uveal melanoma who underwent biopsy compared to nonbiopsied patients (study I). Our finding is based on a complete retrospective national cohort study, performed over three decades, linking clinical and histopathological records to nationwide registry data. The use of continuously updated national registry data allowed for retrieval of exact date of death and an almost complete follow-up (99.7%). We minimized the risk of classification bias, by performing validation of all registry cases through clinical or histopathological Sensitivity of chromosomes 3 and 8 abnormalities of MLPA and FISH results from the biopsy compared to the enucleated eye. records prior to inclusion. The nationwide design avoided referral bias often seen in tertiary single centre studies. Our findings are in accordance with previous case series of intraocular biopsy in uveal melanoma, where no excess mortality has been reported (McCannel et al. 2012 ). However, previous studies have been limited by low patient number, short follow-up and the case-only design, which does not allow for multivariate adjustment of potential confounders. Only a single cohort study has previously reported on metastatic risk among biopsied patients compared to nonbiopsied patients (relative risk=0.988), but the study only included 116 biopsied patients and provided limited information of the nonbiopsied patients (Char et al. 1996) . The lack of an increased metastatic risk following biopsy is further supported by the notion that tumour cells from treatment na€ ıve uveal melanomas have already disseminated at time of diagnosis (Eskelin et al. 2000) . Disseminated tumour cells in patients with no preceding biopsy have been shown in the intratumoral vessels (Ly et al. 2010 ) and in the bone marrow ) at time of diagnosis.
We present the largest retrospective cohort study of mortality risk following transvitreal biopsy of uveal melanoma, but the sample size of 570 biopsied patients is still a limitation. The observational design entails bias as the biopsied patients (35%) represented a selected group of younger patients (p < 0.001) and smaller tumours (p < 0.001) compared to nonbiopsied patients. This was accounted for by performing multivariable adjustment of potential prognostic predictors among the study subjects. In theory, a randomized clinical trial would provide a superior design to exclude a potential dissemination risk following biopsy in uveal melanoma. In reality, such a design could not be defended due to ethical reasons. It would be unethical to deprive half of the patients the opportunity for genetic testing and prognostic counselling. In contrast, if we believed in an increased dissemination risk following biopsy, we would allocate half of the patients to a surgical procedure for the reason of detecting its increased mortality risk.
The determination of cause-specific death introduced reporting bias in our study as different levels of information was available among biopsied and nonbiopsied patients. Thus, melanoma-specific death was underreported in the nonbiopsied group and might explain some of the statistically significantly increased mortality due to other causes (p = 0.002) (Fig. 15) . It is possible that death due to other causes in this group included unidentified melanoma-specific deaths.
Local dissemination can theoretically occur by tumour cells being passively dragged along the needle shaft into the vitreous body and scleral wall or by active migration of tumour cells through the lesion made by the biopsy needle. It is of great importance to minimize seeding risk, as local recurrence caries an increased risk of metastatic disease (Gallie et al. 2016 ). We did not observe any extra ocular tumour seeding in study II, but local recurrence occurred in six cases (8%) and five cases (6.7%) underwent enucleation (study II). This is slightly higher than previously reported enucleation rates of 1% during 1 year and 4% during 2 years of follow-up (The collaborative Ocular Melanoma Study Group 2001).
The limited patient number and follow-up in our case series (study II) prevent conclusive analysis of the matter. However, the minimally invasive TVRC vitrector biopsy possesses several factors, which can theoretically decrease local seeding risk. The intact vitreous decreases the flow inside the eye and thereby potentially reduces intraocular spread of tumour cells. While excisional biopsy directly through the scleral wall (trans-scleral) has previously been found to cause a 15-fold increased incidence of orbital recurrence compared to patients where no biopsy was performed (Jensen & Andersen 1959) . It can be hypothesized that the transvitreal approach provides lower extraocular seeding risk, as the vitreous body retains residual tumour cells from the needle shaft before exiting the eye. Histopathological examination of needle tracts in an experimental setting also revealed a lower number of seeded tumour cells following transvitreal biopsies compared to trans-scleral biopsies (p < 0.001) (Glasgow et al. 1988) . One case of seeding inside the vitreous following transvitreal biopsy has been described in a clinical study (Kim et al. 2017 ), but the clinical significance of seeded tumour cells in the vitreous body is doubtful. We know from animal studies that tumour cells do not grow well in the avascular vitreous (Snell 1951) . Furthermore, spontaneous migration of tumour cells into the vitreous body in treatment na€ ıve patient eyes does not seem to be associated with bad prognosis .
The access through pars plana allows for surveillance of spillover of tumour cells and late local recurrence at the biopsy entry point. Furthermore, the scleral ports, which we have used since 2009, likely reduces the risk of tumour seeding in the sclera (Singh et al. 2017) . However, risk of scleral seeding is not entirely eliminated, demonstrated by a case report of extra ocular recurrence at the scleral port entry site following a transvitreal biopsy (Raja et al. 2011) .
The vitrector system allows for a sufficient biopsy with a single pass compared to trans-scleral biopsies which usually demands several passes and thereby increases the number of seeded tumour cells along the multiple needle tracts (Glasgow et al. 1988; Young et al. 2008 ). In addition, enucleation or brachytherapy is performed during the same operation and thus ensures removal or sterilization of seeded tumour cells inside the eye.
Ocular complications following biopsy
Most vitreoretinal surgery includes complete vitrectomy to prevent remaining vitreous from causing fibrosis and traction of the retina (proliferative retinopathy). In addition, retinal lesions are often treated with laser to prevent inflow of fluid into the subretinal space and thereby retinal detachment. For these reasons, transvitreal biopsy has traditionally been accompanied by full vitrectomy and laser prophylaxis of the retinotomy (Jensen et al. 1997; Bechrakis et al. 2002) . In study II, we examined a case series of minimally invasive biopsies where no vitrectomy was performed and the retinotomy was left untreated. The incidence of second retinal detachment was remarkably low (3.5%) and comparable to the risk of other vitreoretinal surgical procedures. (Tognetto et al. 2006) . Only one case of retinal detachment in our study had a clear indication for surgery due to a subretinal string formation. Even in cases where biopsy was performed through a detached retina, the procedure did not deteriorate the retinal detachment, which resolved spontaneously in all cases. Other case series report incidents of retinal detachment in 0%-11.8% of cases following TVRC vitrector biopsy (Chang & McCannel 2014; Grewal et al. 2017; Nagiel et al. 2017 ) and 1%-2% after transvitreal FNAB (McCannel et al. 2012; Singh et al. 2016) . A large series of 448 consecutive TVRC vitrectomy-assisted biopsies identified a frequency of retinal detachment surgery in 0.4% of cases (Grixti et al. 2014) . Due to limited follow-up information including potential cases lost to follow-up, there is risk of a potential underreporting of complications in this study.
In general, biopsies performed with a vitreous cutter result in higher rates of postoperative haemorrhage compared to FNAB. This is likely due to a more extensive wounding of the intratumoral vasculature. We detected vitreous haemorrhage in 96.5% of patients, of which 82% experienced a clinical significant bleeding. Our finding is comparable to frequencies reported by other case series of vitreous cutter biopsies ranging from 72.2% to 88.9% (Abi-Ayad et al. 2013; Grewal et al. 2017; Nagiel et al. 2017) .
In contrast, transvitreal FNAB case series report vitreous haemorrhages in 24%-65.5% of cases (Cohen et al. 2001; Sellam et al. 2016) . Fine-Needle aspiration biopsy (FNAB) obtained through the trans-scleral approach reports low rates of vitreous haemorrhages ranging from 5.5% to 21% (Young et al. 2008; Sellam et al. 2016) . It has been proposed that performing a full vitrectomy during biopsy can entail a faster resolution of vitreous haemorrhage (Reddy et al. 2017) . In our series (study II), the vitreous haemorrhage cleared spontaneously in most cases and only 5.9% of patients underwent subsequent vitrectomy. However, vitreous haemorrhage significantly affected the VA and quality of life for the patients during the first year following surgery. To improve the visual outcome, we now offer vitrectomy in most cases of dense vitreous haemorrhages that persist 3-6 months after surgery.
We did not observe any cases of endophthalmitis following surgery. This is in accordance with a large case series of 739 consecutive biopsies which reported only one case of endophthalmitis (Grixti et al. 2014) . It is feasible that the heavy radiation following biopsy of uveal melanoma kills potential exogenous bacteria.
Our study was limited by short follow-up and low patient number. We tried to account for different lengths of follow-up by assessing the occurrence of retinal detachment and vitreous haemorrhage with KaplanMeier curves. The main violation of using this analysis to evaluate retinal detachment and other clinical outcomes was that the method treats competing events such as death or enucleation as censored observations instead of competing events.
Evaluation of consequences on VA in regard to the biopsy was challenged as patients with uveal melanoma are concurrently treated with brachytherapy which can cause sight-threatening radiation retinopathy. Visual acuity (VA) at 3 years was only available in 16 patients from study II due to limited follow-up. In addition, our series included diagnoses other than uveal melanoma which makes it less comparable. We therefore provided the data from our consecutive patients with uveal melanoma who underwent TVRC vitrector biopsy between 2009 and 2017 at Rigshospitalet for comparison (Fig. 16) . The fraction of patients that conserved a good VA of 0.5 or better in our series, was similar to other large case series reporting on VA following Ru-brachytherapy (Bergman et al. 2005 ) and I-brachytherapy (The collaborative Ocular Melanoma Study Group 2001) (Fig. 16 ).
Diagnostic and genetic yield
The TVRC vitrectomy-assisted biopsy obtained sufficient material for histopathological diagnosis in 97.6% and genetic testing in 97.3% (study II). In most cases, we obtained excess material, which was stored for later analysis. This is especially alluring in the light of emerging possibilities of genetic tumour profiling and personalized medicine regimes. In comparison, FNAB also provides sufficient material for genetic analysis in most cases (86.4%-96%) (Singh et al. 2016; Shields et al. 2017a ). However, gaining adequate tissue yield from small uveal melanomas poses a challenge (Sen et al. 2006) . The yield from a transvitreal FNAB depends on the cylinder and tumour height and multiple passes are required to increase sample size (Cohen et al. 2001; Bagger et al. 2015) . In contrast the TVRC vitrectomy-assisted biopsy performs continuous suction and cutting by the vitrector tube inside the tumour (Mimura et al. 2012 ). Thus, one or two passes performed with the TVRC vitrectomy-assisted biopsy can obtain the same yield as six to eight passes performed with a trans-scleral FNAB biopsy (Chang & McCannel 2014) . A study of trans-viteral FNAB in tumours of 3 mm or less reported yield for successful diagnostic assessment in 22 cases (64%) (Augsburger et al. 2002) in contrast, the TVRC vitrectomy biopsy reported 100% sufficient sample yield for genetic assessment in uveal melanomas of 2 mm or less (Nagiel et al. 2017) . The possible advantage of the 25G or 27G vitrector biopsies in small tumours is partly caused by the proximity of the lumen and the tip (Fig. 5) , while the 27G Fine-needle have a long bevel which might not be sufficiently embedded in small tumours causing aspiration of vitreous fluid (Nagiel et al. 2017) . Our study II did not allow for assessment of tissue yield in small tumours, as only melanomas of at least 2 mm in height are treated according to Danish national guidelines, thus the minimum tumour height in our study was 2.2 mm.
While some studies only perform genetic testing, we advocate that cytopathological examination is prioritized in addition. Even though noninvasive tests provide high accuracy, a clinical misdiagnosis of uveal melanoma was still reported in 9% of cases, when FNAB was performed to confirm the diagnosis (Char & Miller 1995) . Ensuring a high fraction of melanoma cells is also important for a valid genetic analysis. This is especially important in gene expression profiling as this test does not differentiate between uveal melanoma and other intraocular tumours (Klufas et al. 2015) .
Detection of genetic changes
We demonstrated genetic heterogeneity of copy number for chromosome 8 in 48% of cases while chromosome 3 was only heterogeneously distributed in 13% of cases. The probability of detecting copy number variations of chromosomes 3 and 8 increased towards the base of the tumour (p = 0.049) (Bagger et al. 2015) . Thus, our finding indicates that the site of tissue biopsy can affect the obtained genetic results. This notion is supported by a previous finding of heterogeneity of chromosome 3 in three cases (18%), where alterations in all three cases were located in the basal part of the tumour (Schoenfield et al. 2009 ). The vitreous cutter biopsy allows for sampling at the base of the tumour as the scleral wall can be safely identified with the blunt tip of the vitrector without risk of perforation (Fig. 5) . In addition, the large sample from the vitreous cutter biopsies might mitigate the risk of misclassification due to a broader representation of the tumour. In study III, the TVRC vitrectomyassisted biopsy was able to detect copy number variations of chromosomes 3 in all cases when compared to chromosome 3 status in the matched enucleated eyes. Our findings are in accordance with Coupand et al. who found concordance in regard to chromosome 3 status between biopsy samples (vitreous cutter or excisional) and larger surgical specimens in 27/27 cases (100%) (Coupland et al. 2015) .
We demonstrated that the sensitivity to detect genetic alterations also depends on choice of genetic analysis technique as MLPA resulted in a higher sensitivity compared to FISH. In addition, MLPA analysis has been shown to require less tissue material compared to FISH. The superior sensitivity of MLPA was especially beneficial when detecting partial deletions/gains of chromosomes 3 and 8. The limited ability of FISH to detect partial copy number variations have previously been demonstrated (Lake et al. 2010 ). We used centromere probes for FISH analysis which only detect alterations involving this limited region. In contrast, FISH analysis has been proposed to provide equal sensitivity to MLPA when several probes involving more regions on chromosomes 3p, 3q, 8p and 8q were applied (Vaarwater et al. 2012) . As chromosome 8q holds great prognostic importance, it would be beneficial to include probes which specifically bind to this area in our future analyses. In contrast to MLPA, FISH allows for identification of cases with multiple chromosome copies (polysomy) of the tested chromosomes. Fluorescence in situ hybridization (FISH) evaluates numeric chromosome copy number, as the method is based on direct visualization and counting of chromosomes in the tumour cell nuclei. In contrast, the detection of generalized polysomy is less likely by MLPA, as it is based on a relative estimate of chromosomal material compared to reference chromosomes (Fig. 19) . The prognostic significance of ploidy in uveal melanoma remains to be determined. It has been proposed that lack of BAP1 gene function among polyploid uveal melanoma cases predicts bad prognosis rather than the presence of polyploidy itself (Yavuzyigitoglu et al. 2016a) .
Gene expression profile has been proposed to be unaffected by genetic heterogeneity as it reflects the tumour microenvironment rather than genetic changes in the tumour cells (Onken et al. 2010 ). Augsburger et al. challenged this hypothesis by evaluating GEP of fine-needle aspiration biopsies obtained from two different locations in the same tumour. Discordant results which would have led to different risk assessment was found in 11.3% of cases (Augsburger et al. 2015) . The risk of misclassification in GEP is enhanced by the fact is that the GEP test cannot distinguish between uveal melanoma and other material like blood and retinal tissue (Nagiel et al. 2017 ). Thus a low-risk profile might reflect evaluation of normal tissue rather than the tumour environment.
Stratification of high-risk patients
Currently there is no consensus of which prognostic factors to include in the estimation of survival in patients with uveal melanoma. Based on our results, we propose the combination of two internationally recognized and thoroughly validated prognostication systems, AJCC staging ) and copy number variations of chromosomes 3 and 8q (Shields et al. 2017b) . We found that the assessment of AJCC stage significantly enhanced the prognostic value in patients with abnormal copy number of chromosomes 3 and 8. In contrast, we found a favourable survival in patients with normal copy number of chromosomes 3 and 8 independent of AJCC stage.
We confirmed our findings in a collaborative multicentre study ) and constructed a nomogram to demonstrate how the prognostic factors adhere to a total score, which can accurately estimate survival (Fig. 21) . The nomogram needs to be validated by a large study group to be incorporated into clinical practice. Also, constructing a similar nomogram on a study population with longer follow-up would allow for evaluation of late metastasis. In its present form, the nomogram solely provides evidence of the combined prognostic effect of chromosomal copy number and AJCC staging.
We among others have demonstrated that the frequency of adverse genetic alterations increases with increasing tumour size (Bagger et al. 2015; Shields et al. 2017a ). Still, small tumours less than 2 mm represent a significant risk of metastasis (Malcl es et al. 2015) and has been shown to harbour adverse genetic changes in 24% of cases (Nagiel et al. 2017) .
Incorporation of cytogenetic factors could significantly improve the prognostic value of future AJCC staging systems as previously proposed (Kivel€ a & Kujala 2013 ). The combination would allow for an internationally uniform and feasible prognostication across ocular oncology centres. The fact that cytogenetic and clinical factors should be interpreted together during prognostication, have already been acknowledged by Damato et al. (2007) . They have developed a comprehensive online prognostication tool (LUMPO), which provides accurate individual survival estimates . However, complete reporting of all categories demands detailed histopathological examination by a skilled ocular pathologist. In addition, relative survival is estimated based on general population data of the mainland Britain, which might not be comparable to all populations . Gene expression profile (GEP) has been proposed to provide superior prognostic evaluation independent of other prognostic factors (Onken et al. 2012) . However, the maximum follow-up of the study was limited to 3 years and inclusion of LBD has subsequently been shown to enhance the prognostic accuracy of GEP (Walter et al. 2016) .
Currently, risk stratification of patients with uveal melanoma allow for improved patient counselling and prioritizing of limited resources in the healthcare system by individualized follow-up programs. Patients with almost no risk of metastatic disease can be reassured and spared for extensive follow-up regimens. We have obtained genetic profile by FISH and/ or MLPA in 307 consecutive patients with uveal melanoma during an 8 year period. Almost a third (29%) of the tested patients presented with a normal copy number of chromosomes 3 and 8 and could be reassured of their good prognosis. To date, we have only encountered two patients with metastatic disease among the 89 patients with normal copy number of chromosomes 3 and 8. In one case, cytogenetic assessment was only performed with FISH, which can overlook partial alterations of the chromosomes. Analysis of gene mutations could potentially have identified genetic changes, which we missed by MLPA and FISH in these two cases. Evidence suggest that prognostication might be improved by a combination of copy number variation and gene mutation analyses (Ewens et al. 2014) .
High-risk patients are followed closely with abdominal ultrasonography and chest X-ray to facilitate early detection of metastatic disease. At the present, documentation of a beneficial survival with intensive follow-up is sparse (Augsburger et al. 2009 ). Retrospective evaluation of treatment modalities in metastatic disease is limited by selection and lead time bias (Augsburger et al. 2011) . The observation of improved metastatic survival but lack of improved survival from the time of diagnosis underlines this issue (Augsburger et al. 2009 ). Still, early detection allows for radical liver resection which has been shown to at least prolong metastatic survival in several centres (Mariani et al. 2009; Gomez et al. 2014) . Increasing evidence suggests that uveal melanoma might be a systemic disease with disseminated dormant metastatic cells present at time at diagnosis (Nichols et al. 2017) . The most promising approach to improve survival in high-risk patients with uveal melanoma could therefore be adjuvant therapy at time of primary treatment. Currently, no effective adjuvant agents have been identified for uveal melanoma, but several approaches are tested in randomized clinical trials (Goh & Layton 2016) . The identification of four distinct molecular classes with different driver mutations (BAP1 versus SF3B1) suggest that diverse targeted treatments are needed (Robertson et al. 2017) . Thus genetic profiling prior to entry into clinical trials will likely be of increasing importance in future studies. Also, the identification of frequent GNAQ and GNA11 mutations in uveal melanoma have facilitated several trials with targeting of proteins downstream in the G-protein alpha-q signalling cascade (Harbour & Chao 2014) . Performance of tumour biopsy facilitates this ongoing research in molecular treatments and allow for assessment of genetic alterations in small and medium sized uveal melanomas which would not otherwise be available as they undergo eye-conserving therapies.
Implications
The results of this thesis have significantly improved patient counselling in regard to information on surgical risks associated with the biopsy procedure. By performing genetic prognostication we are able to reassure a third of our patients as their metastatic risk is minimal. Meanwhile we can concentrate our resources to provide increased care and intensified follow-up for patients with high metastatic risk. Evaluation of AJJC stage is performed in all patients and incorporated in the individual prognostic evaluation. To minimize risk of insufficient genetic testing we continuously perform two genetic tests in parallel, including FISH and MLPA. In addition, the combination is beneficial, as MLPA provides high sensitivity while FISH analysis can identify cases with polyploidy. We are currently incorporating BAP1 immunohistochemistry of the biopsy smear at Rigshospitalet to allow for functional evaluation of BAP1 and enhance the accuracy of our genetic prognostication further.
The identification of an increased likelihood to detect copy number variations towards the base of the tumour has guided our surgical biopsy procedure. We now strive to include sampling from the base of the tumour to minimize the risk of genetic misclassification. Our confirmation of the prognostic value of chromosomes 3 and 8 has altered the Danish national guidelines, which now allows for individualized followup programs based on metastatic risk (February 2015) . The results of our study propose that inclusion of genetic information in the AJCC staging system will improve prognostication. The eighth edition of the AJCC staging system published in 2017 does not yet include prognostic factors. However our findings were acknowledged and the importance of including genetic testing in prognostication was emphasized (American Joint Committee on Cancer 2017).
Conclusion
In conclusion, this thesis has provided evidence-based confirmation that clinicians can safely rely on a TVRC vitrector biopsy for accurate prognostication in uveal melanomas.
(1) We found no apparent increase in mortality among patients who underwent TVRC biopsy compared to nonbiopsied patients.
(2) Surgical complications following 25G TVRC vitrector biopsy are manageable and in many cases self-limiting. They include risks of retinal detachment and vitreous haemorrhage. Visual outcome following biopsy was comparable to VA reported by other large series of nonbiopsied patients with uveal melanoma. (3) 25G TVRC vitrector biopsy provides a large sample sufficient for cytological and genetic assessment. We found that the performance of two genetic methods (MLPA and FISH) improved the success rate. (4) We identified genetic heterogeneity of chromosome 8 in approximately half of the uveal melanomas while alterations of chromosome 3 were universally distributed throughout the tumour in most cases. The likelihood of detecting genetic alterations increased towards the base of the tumour. (5) The 25G TVRC vitrector biopsy provided a representative sample for detection of copy number variations of chromosome 3 in 100% of cases and chromosome 8 in 75% of cases. Thus, accurate differentiation between 'high risk' and 'low-risk' patients based on genetic alterations was obtained in all cases. (6) Genetic profile based on the biopsy sample provided accurate estimation of the survival of patients with uveal melanoma. (7) We found that a combination of genetic status and clinical AJCC staging provided the most accurate prognostication in patients with abnormal copy number of chromosomes 3 and 8. In contrast, patients with normal copy number of chromosomes 3 and 8 showed favourable survival independent of AJCC stage. We introduced a nomogram to demonstrate the additive effect of genetic factors and AJCC staging on prognosis.
Perspectives
Further research is needed to facilitate development of new effective targeted treatments, which can improve the stagnated survival in patients with uveal melanoma. Generalized chemotherapeutics with high toxicity and low efficacy are gradually being replaced by a more individualized approach to cancer treatment.
Personalized therapy based on specific oncogenic targets in the individual tumour requires tissue for risk assessment and genetic profiling to select and match patients to the most effective treatment. Thus, continuous development and refinement of tumour sampling in uveal melanoma are warranted in parallel. Intraocular tumour biopsy is a reliable and relatively safe procedure, but it is not risk free. Thus, new techniques for minimally invasive biopsy techniques are alluring. Detection and single cell profiling of circulating tumour cells or circulating tumour DNA in the blood stream could potentially facilitate noninvasive diagnosis and monitoring of uveal melanoma. However, so far studies have produced conflicting results and the method is currently not feasible in clinical practice due to low sensitivity. Aqueous humour might be more prone to reflect the genetic profile of the uveal melanoma. Tumour cells are known to secrete lipid vesicles (exosomes) which can contain genetic material (Ragusa et al. 2015) . So far, exosomes containing highly specific miRNAs have been identified in the vitreous humour from patients with uveal melanoma and might hold great potential for minimally invasive genetic profiling of uveal melanomas in the future (Ragusa et al. 2015) .
